Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges

Why did stocks rise and oil fall after Israel-Iran ceasefire? How did Fed's Powell respond to Trump on interest rates? What caused CareerBuilder + Monster bankruptcy? Why is Tesla's robotaxi facing regulatory scrutiny? How will Kroger's store closures impact the retail sector? What are the effects of proposed Medicaid cuts on hospitals? Why did Disney lay off tech and product staff again?

Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges

benzinga.com/news/health-care/25/06/46080505/amarin-lands-massive-european-commercialization-deal-for-heart-drug-vazkepa-stock-surges

Amarin Corporation Plc (NASDAQ:AMRN) on Tuesday entered into an exclusive long-term license and supply agreement with Recordati S.p.A., Italy, to commercialize Vazkepa (icosapent ethyl) in 59 countries, with a focus on Europe.
Vazkepa (Vascepa in the United States) is indicated to reduce…

This story appeared on benzinga.com, 2025-06-24 17:54:50.